Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Methotrexate effective for pain and inflammation in knee osteoarthritis

Written by | 5 Dec 2020

Article written by Bruce Sylvester Researchers report that methotrexate is an effective treatment for people with knee osteoarthritis (OA) who have pain and inflammation.

Hydroxychloroquine is heart-safe for lupus patients, including those with kidney disease

Written by | 4 Dec 2020

Article written by Bruce Sylvester Hydroxychloroquine treatment for lupus has no significant impact on heart rhythm, researchers reported on Nov 2, 2020 at the American College of Rheumatology/ACR… read more.

Sedentary Behaviour and RA

Written by | 16 Oct 2020

A study by O’Leary and colleagues, which appears in Arthritis Care & Research, looks at sedentary behaviour in people with RA and factors that may be associated with it.

Improved Trials of Rheumatology Drugs?

Written by | 12 Oct 2020

In a study by Rebecca Rothwell and colleagues, which appears in Arthritis & Rheumatology, possible considerations of non-inferiority (NI) trials assessing treatment effects in RA are discussed.

Immuno suppressing drugs do not increase risk for COVID-19

Written by | 25 Sep 2020

Patients on immunosuppressive therapy for common skin and rheumatic diseases like psoriasis and rheumatoid arthritis are not at increased risk for contracting COVID-19 and should continue taking their… read more.

Ferring to market the prefilled syringe formulation of Cimzia in the US for the treatment of Crohn’s disease. UCB + Ferring

Written by | 10 Jul 2020

UCB and Ferring Pharmaceuticals Inc. announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of Cimzia (certolizumab pegol) in the United States, specifically… read more.

Phase III LOTUS study of Stelara in Systemic Lupus Erythematosus discontinued.- Janssen Pharma

Written by | 29 Jun 2020

The Janssen Pharmaceutical Companies of Johnson & Johnson announced its decision to discontinue the Phase III LOTUS study of Stelara (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to… read more.

FDA approves Ilaris to treat adult onset Still’s disease – Novartis

Written by | 24 Jun 2020

The FDA approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA)… read more.

FDA approves Cosentyx to treat active non-radiographic axial spondyloarthritis.- Novartis

Written by | 17 Jun 2020

Novartis, announced that the FDA has approved Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), confirming Cosentyx efficacy in addressing the axial spondyloarthritis (axSpA) disease… read more.

Phase III SELECT trials show Rinvoq efficacy continues to week 84 in rheumatoid arthritis.- AbbVie

Written by | 11 Jun 2020

AbbVie announced new long-term results showing that once-daily Rinvoq (upadacitinib) continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the… read more.

New analyses of phase II EQUATOR clinical program support durable efficacy of filgotinib in psoriatic arthritis.- Gilead Sciences, Inc. + Galapagos NV

Written by | 7 Jun 2020

Gilead Sciences, Inc. and Galapagos NV announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The… read more.

Phase III SELECT-CHOICE trial of Rinvoq meets primary endpoint in rheumatoid arthritis.- AbbVie

Written by | 7 Jun 2020

AbbVie announced new Phase III data from the SELECT-CHOICE clinical trial in adult patients with moderate to severe active rheumatoid arthritis and prior inadequate response or intolerance to… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.